Skip to main content
SpringerLink
Log in

Schwerpunkt triple-negatives Mammakarzinom

Das triple-negative Mammakarzinom — eine Einführung

  • schwerpunkt
  • Published:
InFo Hämatologie + Onkologie Aims and scope

Das triple-negative Mammakarzinom ist ein histomorphologisch und molekulargenetisch heterogener Brustkrebssubtyp. Klinisch zeichnet es sich durch eine schwere Behandelbarkeit aus. Weil gerade junge Fragen betroffen sind, besteht ein besonders hoher Bedarf an wirksamen Therapieansätzen. Diese müssen im Zusammenspiel verschiedener Disziplinen wie etwa der Onkologie, der Radionkologie und auch der Humangenetik (weiter) entwickelt und angewendet werden.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Siegel RL et al. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30

    Article  Google Scholar 

  2. Clarke CA et al. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. J Natl Cancer Inst. 2012;104(14):1094–101

    Article  Google Scholar 

  3. Onitilo AA et al. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009;7(1-2):4–13

    Article  CAS  Google Scholar 

  4. Voduc KD et al. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28(10):1684–91

    Article  Google Scholar 

  5. Hon JD et al. Breast cancer molecular subtypes: from TNBC to QNBC. Am J Cancer Res. 2016;6(9):1864–72

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Mirzania M et al. Approach to the Triple Negative Breast Cancer in New Drugs Area. Int J Hematol Oncol Stem Cell Res. 2016;10(2):115–9

    PubMed  PubMed Central  Google Scholar 

  7. Greenup R et al. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann Surg Oncol. 2013;20(10):3254–8

    Article  Google Scholar 

  8. Copson ER et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 2018;19(2):169–80

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Onkologie und gynäkologisches Tumorzentrum, Universitätsspital Basel, Petersgraben 4, CH-4031, Basel, Schweiz

    Julia Landin &  Marcus Vetter

Authors
  1. Julia Landin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcus Vetter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcus Vetter.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Landin, J., Vetter, M. Das triple-negative Mammakarzinom — eine Einführung. Info Onkol. 22, 10–12 (2019). https://doi.org/10.1007/s15004-019-6467-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-019-6467-3

Search

Navigation